Provided by Tiger Trade Technology Pte. Ltd.

Nurix Therapeutics

15.79
+0.31002.00%
Post-market: 15.790.00000.00%16:10 EST
Volume:953.20K
Turnover:14.89M
Market Cap:1.62B
PE:-5.17
High:15.81
Open:15.49
Low:15.23
Close:15.48
52wk High:22.50
52wk Low:8.18
Shares:102.84M
Float Shares:86.36M
Volume Ratio:1.38
T/O Rate:1.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0514
EPS(LYR):-3.0514
ROE:-49.63%
ROA:-26.30%
PB:3.01
PE(LYR):-5.17

Loading ...

Nurix Therapeutics Chief Legal Officer Christine Ring Reports Disposal of Common Shares

Reuters
·
Feb 10

Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration

Simply Wall St.
·
Feb 09

Stock Track | Nurix Therapeutics Plummets 5% Intraday on Q4 Losses and Foreign Exchange Risk Concerns

Stock Track
·
Jan 30

Nurix Therapeutics (NRIX) Q4 Loss Highlights Ongoing Profitability Concerns Despite Revenue Progress

Simply Wall St.
·
Jan 30

Nurix Therapeutics Exposed to Significant Foreign Exchange Risk Amid Unhedged Currency Exposure

TIPRANKS
·
Jan 30

Nurix Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jan 30

Stock Track | Nurix Therapeutics Soars 5.90% in Intraday Trading on Positive Analyst Ratings

Stock Track
·
Jan 29

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) and Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Jan 29

RBC Raises Price Target on Nurix Therapeutics to $30 From $28, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 29

Nurix Therapeutics Price Target Maintained With a $26.00/Share by Needham

Dow Jones
·
Jan 29

Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright

TIPRANKS
·
Jan 29

Nurix Therapeutics reports Q4 EPS (82c), consensus (92c)

TIPRANKS
·
Jan 29

Australia's Nurix Therapeutics Q4 net loss widens

Reuters
·
Jan 29

Nurix Therapeutics Appoints Roger Dansey to Board of Directors

Reuters
·
Jan 29

Nurix Therapeutics Q4 EPS $(0.82) Beats $(0.92) Estimate, Sales $13.577M Miss $14.309M Estimate

Benzinga
·
Jan 29

Nurix Therapeutics Q4 Net Income USD -78.221 Million

THOMSON REUTERS
·
Jan 29

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

GlobeNewswire
·
Jan 29

Nurix Therapeutics Chief Legal Officer Christine Ring Reports Disposal of Common Shares

Reuters
·
Jan 21

RBC Trims Price Target on Nurix Therapeutics to $28 From $29, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 20

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX)

TIPRANKS
·
Jan 16